Human hepatoblastoma (HB) is the most common pediatric liver cancer in the U.S.A. More than 30 percent of patients die after a 10-year period. In addition, the existing therapies are very costly. For example, liver transplantation is estimated to cost approximately $150,000 to $200,000 per patient. Moreover, the shortage of donor livers for patients awaiting transplant and graft rejection post-transplantation significantly limit the widespread usage of this method. Thus, alternative therapies are still warranted.
Fighting childhood cancer, one cup at a time.
